Oxidative stress in end-stage renal disease: an emerging threat to patient outcome.
暂无分享,去创建一个
[1] Z. Massy,et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] C. Zoccali,et al. Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. , 2001, Journal of nephrology.
[3] S. Hazen,et al. Peroxidases inhibit nitric oxide (NO) dependent bronchodilation: development of a model describing NO-peroxidase interactions. , 2001, Biochemistry.
[4] J. Blumberg,et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. , 2001, Kidney international.
[5] C. Wanner,et al. Advanced glycation end products and mortality in hemodialysis patients. , 2002, Kidney international.
[6] F. Locatelli,et al. Changes in the clinical condition of haemodialysis patients. , 1999, Journal of nephrology.
[7] J. Jankowski,et al. The Antioxidant Acetylcysteine Reduces Cardiovascular Events in Patients With End-Stage Renal Failure: A Randomized, Controlled Trial , 2003, Circulation.
[8] F Locatelli,et al. Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] Brunner Fp,et al. Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. , 1992 .
[10] S. Grundy,et al. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. , 2000, Atherosclerosis.
[11] H. Sies,et al. Oxidative stress: oxidants and antioxidants , 1997, Experimental physiology.
[12] J. Cristol,et al. Imbalance of Oxidants and Antioxidants in Haemodialysis Patients , 1999, Blood Purification.
[13] J. Weiter,et al. Oral α-Tocopherol Supplements Decrease Plasma γ-Tocopherol Levels in Humans , 1985 .
[14] J. Weiter,et al. Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans. , 1985, The Journal of nutrition.
[15] A. Chait,et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease☆ , 2002 .
[16] D. Tarng,et al. 8-hydroxy-2'-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] G. Handelman. Evaluation of Oxidant Stress in Dialysis Patients , 2000, Blood Purification.
[18] M. Boaz,et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial , 2000, The Lancet.
[19] D. Harrison,et al. Endothelial Regulation of Vasomotion in ApoE-Deficient Mice: Implications for Interactions Between Peroxynitrite and Tetrahydrobiopterin , 2001, Circulation.
[20] E. Friedman,et al. Advanced glycosylation end products in patients with diabetic nephropathy. , 1991, The New England journal of medicine.
[21] P. Jungers,et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. , 1998, Journal of immunology.
[22] E J Topol,et al. Association between myeloperoxidase levels and risk of coronary artery disease. , 2001, JAMA.
[23] B. Descamps-Latscha,et al. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. , 1985, Kidney international.
[24] Z. Massy,et al. Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients. , 1999, Kidney international.
[25] W. Pryor. Oxy-radicals and related species: their formation, lifetimes, and reactions. , 1986, Annual review of physiology.
[26] L. Chiarantini,et al. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. , 1998, Kidney international.
[27] O. Sommerburg,et al. Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[28] B. Ames,et al. γ-Tocopherol and its major metabolite, in contrast to α-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells , 2000 .
[29] M. Hijmering,et al. Nitric oxide production is reduced in patients with chronic renal failure. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[30] M. Boaz,et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. , 1999, Kidney international.
[31] M. F. Weiss,et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. , 2000, Kidney international.
[32] P. Stenvinkel,et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. , 2003, Kidney international. Supplement.
[33] A. Coats. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .
[34] W. Koenig,et al. C-Reactive Protein in the Arterial Intima: Role of C-Reactive Protein Receptor–Dependent Monocyte Recruitment in Atherogenesis , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[35] S. Bode-Böger,et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. , 1999, Journal of the American Society of Nephrology : JASN.
[36] T. Meinertz,et al. Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease , 2001, Circulation.
[37] Loyd,et al. SIMVASTATIN AND NIACIN , ANTIOXIDANT VITAMINS , OR THE COMBINATION FOR THE PREVENTION OF CORONARY DISEASE , 2001 .
[38] F. Brunner,et al. Profile of patients on RRT in Europe and death rates due to major causes of death groups. The EDTA Registration Committee. , 1992, Kidney international. Supplement.
[39] P. Jungers,et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. , 1996, Kidney international.
[40] E. Schleicher,et al. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.
[41] F. Leighton,et al. Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. , 2001, Kidney international.
[42] T. Imaizumi,et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. , 2000, Circulation.
[43] C. Zoccali,et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.
[44] C van Ypersele de Strihou,et al. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. , 1999, Kidney international.
[45] M. Kazatchkine,et al. Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: a randomized prospective study. , 1991, Nephron.
[46] C. Zoccali. Cardiovascular risk in uraemic patients-is it fully explained by classical risk factors? , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[47] C. Wanner,et al. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? , 2001, Kidney international. Supplement.
[48] M. Pfeffer,et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[49] B. Descamps-Latscha,et al. Dialysis‐Induced Oxidative Stress: Biological Aspects, Clinical Consequences, and Therapy , 2001, Seminars in dialysis.
[50] K. Feingold,et al. Infection and inflammation induce LDL oxidation in vivo. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[51] M. Brown,et al. A Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: The Cambridge Heart Antioxidant Study (CHAOS) , 1996 .
[52] B. Ames,et al. gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[53] R. Luke. Chronic renal failure--a vasculopathic state. , 1998, The New England journal of medicine.